Global trends in typhoid and paratyphoid fever

Clinical Infectious Diseases

Volumn 50, Issue 2, 2010, Pages 241-246

  Crump, John A ^a,b,c,d   Mintz, Eric D ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b DUKE UNIVERSITY   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; GATIFLOXACIN; LIVE VACCINE; NALIDIXIC ACID; POLYSACCHARIDE VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TYPHOID VACCINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ASIA; BACTERIAL GENOME; CLINICAL TRIAL; ENDEMIC DISEASE; FOOD; GENE DELETION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; IMMUNOGENICITY; INCIDENCE; INFECTION CONTROL; PARATYPHOID FEVER; PRIORITY JOURNAL; REVIEW; SALMONELLA ENTERICA; SALMONELLOSIS; SANITATION; SEROTYPE; SINGLE DRUG DOSE; SOUTHEAST ASIA; TYPHOID FEVER;

DRUG RESISTANCE, BACTERIAL; HUMANS; PARATYPHOID FEVER; TYPHOID FEVER; WORLD HEALTH;

EID: 73649135423     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/649541     Document Type: Review

References (55)

1. Whitaker JA, Franco-Paredes C, del Rio C, Edupuganti S. Rethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areas. J Travel Med 2009; 16:46-52.
2. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004; 82:346-353
3. Crump JA, Youssef FG, Luby SP, et al. Estimating the incidence of typhoid fever and other febrile illnesses in developing countries. Emerg Infect Dis 2003; 9:539-544
4. Gilman RH, Terminel M, Levine MM, Hernandez-Mendoza P, Hornick RB. Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella Typhi in typhoid fever. Lancet 1975; 1:1211-1213
5. Olsen SJ, Pruckler J, Bibb W, et al. Evaluation of rapid diagnostic tests for typhoid fever. J Clin Microbiol 2004; 42:1885-1889 (Pubitemid 38637797)
6. Chart H, Cheasty T, De Pinna E, et al. Serodiagnosis of Salmonella enterica serovar Typhi and S. enterica scrovars Paratyphi A, B and C human infections. J Med Microbiol 2007; 56:1161-1166
7. Archibald LK, Reller LB. Clinical microbiology in developing countries. Emerg Infect Dis 2001; 7:302-305
8. Crump JA, Ram PK, Gupta SK, Miller MA, Mintz ED. Part 1. Analysis of data gaps pertaining to Salmonella enterica serotype Typhi infections in low and medium human development index countries, 1984-2005. Epidemiol Infect 2008; 136:436-448
9. Shaw AV, Reddy EA, Crump JA. Etiology of community-acquired bloodstream infections in Africa [abstract L-620]. In: Program and absracts of the 46th Annual Meeting of the Infectious Diseases Society of America. Washington, DC: Infectious Diseases Society of America, 2008.
10. Mweu E, English M. Typhoid fever in children in Africa. Trop Med Int Health 2008; 13:1-9.
11. Muyembe-Tamfum JJ, Veyi J, Kaswa M, Lunguya O, Verhaegen J and Boelaert M. An outbreak of peritonitis caused by multidrug-resistant Salmonella Typhi in Kinshasa, Democratic Republic of Congo. Travel Med Infect Dis 2009; 7:40-43
12. Ochiai RL, Acosta CJ, Danovaro-Holliday MC, et al. A study of typhoid fever in five Asian countries: disease burden and implications for control. Bull World Health Organ 2008; 86:260-268
13. Woods CW, Murdoch DR, Zimmerman MD, et al. Emergence of Salmonella enterica serotype Paratyphi A as a major cause of enteric fever in Kathmandu, Nepal. Trans R Soc Trop Med Hyg 2006; 100:1063-1067
14. Ochiai RL, Wang XY, von Seidlein L, et al. Salmonella Paratyphi A rates, Asia. Emerg Infect Dis 2005; 11:1764-1766
15. Anonymous. Typhoid in the large cities of the United States in 1919: eighth annual report. JAMA 1920; 74:672-675
16. Clasen T, Schmidt W-P, Rabie T, Roberts I, Cairncross S. Interventions to improve water quality for preventing diarrhoea: systematic review and meta-analysis. Brit Med J 2007; 334:782. (Pubitemid 46650122)
17. Engleberg NC, Barrett TJ, Fisher H, Porter B, Hurtado E, Hughes JM. Identification of a carrier by using Vi enzyme-linked immunosorbent assay serology in an outbreak of typhoid fever in an Indian reservation. J Clin Microbiol 1983; 18:1320-1322 (Pubitemid 14235624)
18. Gupta A, My Thanh NT, Olsen SJ, et al. Evaluation of communitybased serologic screening for identification of chronic Salmonella Typhi carriers in Vietnam. Int J Infect Dis 2006; 10:309-314
19. Sur D, Ochiai RL, Bhattacharya SK, et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med 2009; 361:335-344
20. Lin FY, Ho VA, Kheim HB, et al. The efficacy of a Salmonella Typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344:1263-1269
21. Tacket CO, Levine MM. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clin Infect Dis 2007; 45:S20-8.
22. Levine MM, Ferreccio C, Black RE, Lagos R, Martin OS, Blackwelder WC. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica serovar Paratyphi B. Clin Infect Dis 2007; 45:S24-8.
23. Meltzer E, Sadik C, Schwartz E. Enteric fever in Israeli travelers: a nationwide study. J Travel Med 2005; 12:275-281 (Pubitemid 43074390)
24. Ruan P, Xia X-P, Sun D, et al. Recombinant SpaO and Hla as immunogens for protection of mice from lethal infections with Salmonella Paratyphi A: implications for rational design of typhoid fever vaccines. Vaccine 2008; 26:6639-6644
25. Arya SC, Sharma KB. Urgent need for effective vaccine against Salmonella Paratyphi A, B and C. Vaccine 1995; 13:1727-1728
26. Levine MM. Mass vaccination to control epidemic and endemic typhoid fever. Curr Top Microbiol Immunol 2006; 304:231-246
27. deRoeck D, Ochiai RL, Yang J, Anh DD, Alag V, Clemens JD. Typhoid vaccination: the Asian experience. Expert Rev Vaccines 2008; 7:547-560
28. Ochiai RL, Acosta CJ, Agtini M, et al. The use of typhoid vaccines in Asia: the DOMI experience. Clin Infect Dis 2007; 45:S34-8.
29. Typhoid vaccines: WHO position paper. Wkly Epidemiol Rec 2008; 83:49-59.
30. Yang HH, Kilgore PE, Yang LH, et al. An outbreak of typhoid fever, Xing-An county, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine. J Infect Dis 2001; 183:1775-1780
31. Edelman R, Levine MM. Summary of an international workshop on typhoid fever. Rev Infect Dis 1986; 8:329-349
32. Rowe B, Ward LR, Threlfall EJ. Multidrug-resistant Salmonella Typhi: a worldwide epidemic. Clin Infect Dis 1997; 24:S106-9.
33. Gupta SK, Medalla F, Omondi MW, et al. Laboratory-based surveillance of paratyphoid fever in the United States: travel and antimicrobial resistance. Clin Infect Dis 2008; 46:1656-1663
34. Parry CM, Threlfall EJ. Antimicrobial resistance in typhoidal and nontyphoidal salmonellae. Curr Opin Infect Dis 2008; 21:531-538
35. Maskey AP, Basnyat B, Thwaites GE, Campbell JI, Farrar JJ, Zimmerman MD. Emerging trends in enteric fever in Nepal: 9124 cases confirmed by blood culture 1993-2003. Trans R Soc Trop Med Hyg 2008; 102:91-95
36. Sood S, Kapil A, Das B, Jain Y, Kabra SK. Re-emergence of chloramphenicol-sensitive Salmonella Typhi. Lancet 1999; 353:1241-1242
37. Lynch MF, Blanton EM, Bulens S, et al. Typhoid fever in the United States, 1999-2006. JAMA 2009; 302:859-865
38. Brown JC, Thomson CJ, Amyes SGB. Mutations of the gyrA gene of clinical isolates of Salmonella Typhimurium and three other Salmonella species leading to decreased susceptibilities to 4-quinolone drugs. J Antimicrob Chemother 1996; 37:351-356
39. Crump JA, Barrett TJ, Nelson JT, Angulo FJ. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin Infect Dis 2003; 37:75-81.
40. Threlfall EJ, Ward LR, Skinner JA, Smith HR, Lacey S. Ciprofloxacinresistant Salmonella Typhi and treatment failure. Lancet 1999; 353:1590-1591
41. Crump JA, Kretsinger K, Gay K, et al. Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States FoodNet multicenter retrospective cohort study. Antimicrob Agents Chemother 2008; 52:1278-1284
42. Chuang C-H, Su LH, Perera J, et al. Surveillance of antimicrobial resistance in Salmonella entérica serotype Typhi in seven Asian countries. Epidemiol Infect 2009; 137:266-269
43. Al Naiemi N, Zwart B, Rijnsburger MC, et al. Extended-spectrumbeta- lactamase production in a Salmonella entérica serotype Typhi strain from the Philippines. J Clin Microbiol 2008; 46:2794-2795
44. Pokharel BM, Koirala J, Dahal RK, Mishra SK, Khadga PK, Tuladhar NR. Multidrug-resistant and extended-spectrum beta-kctamase (ESBL)-producing Salmonella enterica (serotypes Typhi and Paratyphi A) from blood isolates in Nepal: surveillance of resistance and a search for newer alternatives. Int J Infect Dis 2006; 10:434-438
45. Nordmann P, Poirel L, Mak JK, White PA, McIver CJ, Taylor P. Multidrug-resistant Salmonella strains expressing emerging antibiotic resistance determinants. Clin Infect Dis 2008; 46:324-325
46. Pandit A, Arjyal A, Day JN, et al. An open randomised comparison of gatifloxacin versus Cefixime for the treatment of uncomplicated enteric fever. PLoS ONE 2007; 2:e524.
47. Effa EE, Bukirwa H. Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever). Cochrane Database of Systematic Reviews 2008; 4:CD006083.
48. Dolecek C, La TTP, Rang NN, et al. A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam. PLoS ONE 2008; 3:e2188.
49. Parkhill J, Dougan G, James KD, et al. Complete genome sequence of a multidrug resistant Salmonella enterica serovar Typhi CT18. Nature 2001; 413:848-852
50. Deng W, Liou SR, Plunkett G, et al. Comparative genomics of Salmonella enterica serovar Typhi strains Ty2 and CT18. J Bacteriol 2003; 185:2330-2337
51. McClelland M, Sanderson KE, Clifton SW, et al. Comparison of genome degradation in Paratyphi A and Typhi, human-restricted serovars of Salmonella enterica that cause typhoid. Nature Genetics 2004; 36:1268-1274
52. Kidgell C, Reichard U, Wain J, et al. Salmonella Typhi, the causative agent of typhoid fever is approximately 50,000 years old. Infect Genet Evol 2002; 2:39-45.
53. Holt KE, Thomson NR, Wain J, et al. Pseudogene accumulation in the evolutionary histories of Salmonella entérica serovars Paratyphi A and Typhi. BMC Genomics 2009; 10:36.
54. Achtman M. Evolution, population structure, and phylogeography of genetically monomorphic bacterial pathogens. Annu Rev Microbiol 2008; 62:53-70.
55. Centers for Disease Control and Prevention. Typhoid and paratyphoid fever. In: US Department of Health and Human Services, ed. CDC Health Information for Interational Travel 2010. Atlanta, GA: Centers for Diseases Control and Prevention, 2009.